(Reuters) -PerkinElmer Inc on Monday agreed to sell three of its businesses to private equity firm New Mountain Capital for up to $2.45 billion in cash, as it looks to focus on its life sciences and ...

PerkinElmer is slimming down to focus solely on diagnostics and life sciences research, selling off its other businesses in a deal that will hand it $2.3 billion in cash. The funding is expected to ...

PerkinElmer, Inc. PKI is well poised for growth, courtesy of a robust product portfolio and impressive margin expansion. However, forex remains a concern. Shares of this currently Zacks Rank #3 (Hold) ...

PerkinElmer is acquiring Covaris, which manufactures applications and solutions for life science companies, as part of an effort to expand its life sciences portfolio. The biotech announced Monday ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Nine months after announcing it ...

PerkinElmer said today it agreed to acquire BioLegend, a provider of life science antibodies and reagents, for approximately $5.25 billion in cash and stock—the largest acquisition in the buyer’s ...

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that it has priced an offering of $500.0 million ...

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) today announced it has entered into an agreement to acquire BioLegend, a leading, global provider of life science ...